New hope for tough leukemia: drug combo enters early trials
NCT ID NCT07508982
First seen Apr 09, 2026 · Last updated May 01, 2026 · Updated 5 times
Summary
This early-phase trial tests whether adding a new drug (APG1252) to standard chemotherapy (AZA) can help control high-risk acute myeloid leukemia (AML). About 52 adults with relapsed, refractory, or certain newly diagnosed AML will take part. The main goal is to check safety and see if the combination slows the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT MD Anderson
Houston, Texas, 77030, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.